Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer

Jennifer A. Byrne(The University of Sydney), Anna DeFazio(The University of Sydney), Karen Byth(Westmead Hospital), Gregory B. Peters(Children's Hospital at Westmead), Luke St Heaps(Children's Hospital at Westmead), Dennis J. Slamon(University of California, Los Angeles), Yael Livnat(The University of Sydney), Janelle Mercieca(Children's Hospital at Westmead), Paul R. Harnett(The University of Sydney), Beth Y. Karlan(University of California, Los Angeles), Rosemary L. Balleine(The University of Sydney), Marlena S. Fejzo(University of Southern California), Yoke‐Eng Chiew(The University of Sydney)
International Journal of Cancer
June 28, 2005
10.1002/ijc.21250
Cited by 99

Related Papers

Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k